About 21 Trademarks found that are owned by Gw Pharma Limited

Education services, namely, providing non-downloadable webinars in the fields of medicine, healthcare, and disease management; On-line journals, namely, blogs featuring information, news and commentary in the fields of medicine, healthcare, and disease management; Educational services, namely, conducting seminars, classes, workshops, and conferences in the fields of medicine, healthcare, and disease management, and distribution of training materials in connection therewith

The mark consists of the wording "EPIDIALOGUES" and a speech bubble, in which the first letter "I" is integrated within the outline of the speech bubble, the letters "EP" are outside the speech bubble, and the letters "DIALOGUES" are inside the speech bubble.

Educational services, namely, conducting seminars, classes, workshops, and conferences in the fields of medicine, healthcare, and disease management, and distribution of educational materials in connection therewith; On-line journals, namely, blogs featuring information, news and commentary in the fields of medicine, healthcare, and disease management; Education services, namely, providing non-downloadable webinars in the field of medicine, healthcare, and disease management

Providing medical information; Providing online medical information; Providing a website featuring information in the field of neurological health, brain disorders, and medicine

Pharmaceutical and medical preparations and substances in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols, for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; pharmaceutical and medical preparations with cannabinoids as active ingredient, namely, a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; pharmaceutical preparations and substances for the treatment of epilepsy associated with Dravet Syndrome and Lennox-Gestaut Syndrome in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; pharmaceutical preparations and substances for the treatment of convulsions and seizures associated with epilepsy associated with Dravet Syndrome and Lennox-Gestaut Syndrome in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; pharmaceutical and medical preparations for the treatment of symptoms associated with epilepsy including pain, muscle spasticity and spasms, bladder problems and sleep disorders associated with Dravet Syndrome and Lennox-Gestaut Syndrome in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; medicinal oils in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; medicinal infusions in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of epilepsy, convulsions and seizures associated with Dravet Syndrome and Lennox-Gestaut Syndrome

Pharmaceutical and medical preparations and substances in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols, for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; pharmaceutical and medical preparations with cannabinoids as active ingredient, namely, a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; pharmaceutical preparations and substances for the treatment of epilepsy associated with Dravet Syndrome and Lennox-Gestaut Syndrome in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; pharmaceutical preparations and substances for the treatment of convulsions and seizures associated with epilepsy associated with Dravet Syndrome and Lennox-Gestaut Syndrome in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; pharmaceutical and medical preparations for the treatment of symptoms associated with epilepsy including pain, muscle spasticity and spasms, bladder problems and sleep disorders associated with Dravet Syndrome and Lennox-Gestaut Syndrome in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; medicinal oils in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; medicinal infusions in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of epilepsy, convulsions and seizures associated with Dravet Syndrome and Lennox-Gestaut Syndrome

Pharmaceutical and medical preparations and substances in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols, for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; pharmaceutical and medical preparations with cannabinoids as active ingredient, namely, a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; pharmaceutical preparations and substances for the treatment of epilepsy associated with Dravet Syndrome and Lennox-Gestaut Syndrome in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; pharmaceutical preparations and substances for the treatment of convulsions and seizures associated with epilepsy associated with Dravet Syndrome and Lennox-Gestaut Syndrome in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; pharmaceutical and medical preparations for the treatment of symptoms associated with epilepsy including pain, muscle spasticity and spasms, bladder problems and sleep disorders associated with Dravet Syndrome and Lennox-Gestaut Syndrome in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; medicinal oils in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; medicinal infusions in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of epilepsy, convulsions and seizures associated with Dravet Syndrome and Lennox-Gestaut Syndrome

"BIOSCIENCES"

Scientific and technological services, namely, scientific research, analysis, testing in the field of medicines, healthcare, and cancer treatment, and research and new product design services relating thereto, all not involving cannabinoid medicines; chemical analysis not involving cannabinoid medicines; chemical research not involving cannabinoid medicines; research and development in the field of medicines, healthcare, and cancer treatment, not involving cannabinoid medicines; and Scientific and technological services, namely, scientific research, analysis, testing in the field of cannabinoid medicine development, and research and new product design services relating thereto, all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; chemical analysis involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; chemical research involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; research and development in the field of cannabinoid medicines involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols

Paper; cardboard and goods made from these materials, namely, boxes of cardboard; printed matter, namely, magazines devoted to medicine, healthcare, cancer treatment and cannabinoid medicines, books and pamphlets in the field of medicine, healthcare, cancer treatment and cannabinoid medicines, printed periodicals, general features magazines, employee newsletters all in the fields of medicine, healthcare, cancer treatment and cannabinoid medicines; books in the field of medicine, healthcare, cancer treatment and cannabinoid medicines; printed publications, namely, newspapers in the field of medicine, healthcare, cancer treatment and cannabinoid medicines; packaging materials for packages, namely, packaging containers of paper and cardboard; wrapping materials for packages, namely, wrapping paper, plastic film, plastic insulating materials, plastic protective wrapping; packaging boxes of paper, card or cardboard; stationery; printed instructional and teaching material in the field of medicines, healthcare, cancer treatment and cannabinoid medicines

"BIOSCIENCES"

Pharmaceutical and veterinary preparations for use in treating pain, neuropathic pain, cancer pain, multiple sclerosis, spinal cord injury, bladder dysfunction, peripheral neuropathy, spasticity, cancer and cancer symptoms, perioperative pain, rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, hypoxic-ischaemic encephalopathy, symptoms of neurogenic disorders, movement disorders, essential tremors, psychotic disorders, diseases of the central nervous system, stroke and head injuries, motion sickness and chemically induced sickness, spasticity, psychiatric illnesses, post-traumatic stress disorder, neurodegenerative diseases, metabolic disorders, obesity, obesity associated with Type II Diabetes, bulimia, schizophrenia, Crohn's disease, Alzheimer's disease, bone disorders, inflammatory disorders, sleep and sleep disorders, and drug, alcohol, and nicotine abuse; herbs for medicinal purposes; medicinal herbs; medicinal oils; medicinal infusions for use in treating pain, neuropathic pain, cancer pain, multiple sclerosis, spinal cord injury, bladder dysfunction, peripheral neuropathy, spasticity, cancer and cancer symptoms, perioperative pain, rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, hypoxic-ischaemic encephalopathy, symptoms of neurogenic disorders, movement disorders, essential tremors, psychotic disorders, diseases of the central nervous system, stroke and head injuries, motion sickness and chemically induced sickness, spasticity, psychiatric illnesses, post-traumatic stress disorder, neurodegenerative diseases, metabolic disorders, obesity, obesity associated with Type II Diabetes, bulimia, schizophrenia, Crohn's disease, Alzheimer's disease, bone disorders, inflammatory disorders, sleep and sleep disorders, and drug, alcohol, and nicotine abuse; pure extracts of medicinal plants and herbs; foodstuffs for medicinal purposes, namely, dietetic foods adapted for medical use; herb teas for medicinal purposes

Downloadable webinars in the field of medicine, healthcare, and disease management